about
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapyB3-lesions of the breast and cancer risk - an analysis of mammography screening patients.Different prognostic value of circulating and disseminated tumor cells in primary breast cancer: Influence of bisphosphonate intake?
P50
description
onderzoeker
@nl
name
Ann-Kathrin Bittner
@ast
Ann-Kathrin Bittner
@en
Ann-Kathrin Bittner
@es
type
label
Ann-Kathrin Bittner
@ast
Ann-Kathrin Bittner
@en
Ann-Kathrin Bittner
@es
prefLabel
Ann-Kathrin Bittner
@ast
Ann-Kathrin Bittner
@en
Ann-Kathrin Bittner
@es